4D Molecular Therapeutics, Inc. (FDMT) · Aug 13, 2026 · Earnings

The quarter barely moved estimates; the $200M facility is the real signal

In line — GAAP EPS $(1.04) vs roughly $(1.03) consensus; revenue $3.8M vs roughly $3.79M consensus

EPS came in just below consensus, but revenue matched and a new Hercules facility strengthens liquidity ahead of 2027 Phase 3 readouts.

The quarter was broadly in line with expectations, not a clean beat. Reported GAAP EPS was $(1.04), just below the published consensus near $(1.03), while collaboration revenue of $3.8 million was essentially in line with estimates near $3.79 million.

MetricQ2 2026Q2 2025Market read
Collaboration and license revenue$3.8M$0.0MRoughly in line with ~$3.79M consensus (Statements of Operations)
R&D expense$68.3M$48.0MUp 42%, reflecting Phase 3 execution (Statements of Operations)
Net loss$(72.9)M$(54.7)MWider loss as development spending rises (Statements of Operations)
GAAP EPS$(1.04)$(0.98)Slightly below roughly $(1.03) consensus (Statements of Operations)
Cash, equivalents and marketable securities$430.6M$514.0M at Dec. 31, 2025Cash declined during the first half (Balance Sheet Data)

The real incremental news is financing flexibility, not the income statement. 4DMT secured a Hercules credit facility of up to $200 million and drew $20 million initially (Corporate Highlights). That adds optional liquidity, but it is debt rather than nondilutive funding; the company still says its current operating plan is funded into the second half of 2028 based on cash and expected Otsuka payments (Cash Position).

Clinical execution remains on schedule, but the decisive evidence is still far away. Enrollment is complete for both wet-AMD Phase 3 studies, with topline data expected in Q2 2027 for 4FRONT-1 and the second half of 2027 for 4FRONT-2 (4D-150 for Wet AMD). The encouraging PRISM two-year data were already presented on July 18, 2026, so that evidence is partly known rather than a fresh surprise (PRISM Phase 1/2 Clinical Trial).

The net read is mixed: steady progress, but no new efficacy inflection. The filing preserves the 4D-150 timeline and strengthens balance-sheet flexibility, while the quarter itself slightly missed on EPS and carries materially higher R&D costs. With the major wet-AMD readouts not due until 2027, the October 21 Investor Day is the next named event likely to add commercial detail (Corporate Highlights).

What to watch next

Investor Day in New York, October 21, 2026

Original filing on SEC EDGAR

More 4D Molecular Therapeutics, Inc. news

The quarter barely moved estimates; the $200M facility is the real signal | FDMT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.